Annual Report

Overview

The report presents the company's FY21 response to COVID-19 and patient-access needs, including repurposed Itolizumab and continuity of medicine supply. Consolidated revenue grew 14% to ₹73,603 million, while renewable energy reached approximately 53% of overall consumption. The report also introduced the Group's first ESG Summary Report alongside the Annual Report.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: 1 April 2020 – 31 March 2021
Language: English
Pages
File size
Restatement: Disclosed

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services